Market Overview
| Study Period | 2022 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Base Year Market Size (2025) | USD 6.82 Billion |
| Market Size (2026) | USD 7.52 Billion |
| Market Size (2031) | USD 12.29 Billion |
| Growth Rate (2026 - 2031) | 10.31% CAGR |
| Market Concentration | Low |
Major Players *Disclaimer: Major Players sorted in no particular order Image 漏 麻豆视频. Reuse requires attribution under CC BY 4.0. | |
Europe Genetic Testing Market Analysis by 麻豆视频
The Europe genetic testing market size is expected to grow from USD 6.82 billion in 2025 to USD 7.52 billion in 2026 and is forecast to reach USD 12.29 billion by 2031 at 10.31% CAGR over 2026-2031. Robust growth reflects the continent鈥檚 cohesive precision-medicine policies under the EU In Vitro Diagnostic Regulation (IVDR), sharp declines in sequencing costs, and expanded newborn as well as population-level genomic screening programs. Tumor profiling, hereditary-cancer testing, and direct-to-consumer wellness kits underpin demand as hospitals embed molecular diagnostics into oncology, rare-disease, and pharmacogenomics pathways. Meanwhile, IVDR-driven quality requirements and the region鈥檚 integrated electronic-health-record architecture encourage laboratories to adopt automated next-generation sequencing (NGS) workflows that shorten turnaround times and support same-week clinical decision making. Competition intensifies as platform leaders acquire complementary omics assets, exemplified by Illumina鈥檚 USD 350 million purchase of SomaLogic in 2024, while mid-tier laboratories consolidate to meet CE-IVD certification thresholds.
Key Report Takeaways
- By technology, NGS held 40.62% of Europe genetic testing market share in 2025, whereas PCR platforms are projected to record the fastest 10.91% CAGR to 2031.
- By application, cancer diagnosis & prognosis captured 47.10% of Europe genetic testing market size in 2025, while ancestry & wellness testing is anticipated to expand at a 11.05% CAGR between 2026-2031.
- By end user, hospitals & clinics accounted for 51.44% of Europe genetic testing market share in 2025; diagnostic laboratories are set to post the highest 11.55% CAGR through 2031.
- By geography, Germany led with a 24.05% contribution to Europe genetic testing market size in 2025, whereas Rest of Europe鈥攁nchored by Eastern EU members鈥攚ill rise at a 11.72% CAGR over the forecast horizon.
Note: Market size and forecast figures in this report are generated using 麻豆视频鈥檚 proprietary estimation framework, updated with the latest available data and insights as of 2026.
Europe Genetic Testing Market Trends and Insights
Drivers Impact Analysis*
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Growing adoption of NGS-based comprehensive panels | +2.1% | Germany, UK, France, Nordic countries | Medium term (2-4 years) |
| Expansion of newborn and population genomic screening programs | +1.8% | Belgium, UK, Netherlands, Central Europe | Long term (鈮� 4 years) |
| Falling sequencing costs from regional infrastructure investment | +1.4% | Germany, UK, France | Short term (鈮� 2 years) |
| Rising prevalence of hereditary cancers boosting BRCA & multigene demand | +1.2% | UK, Germany, France | Medium term (2-4 years) |
| EU IVDR-led shift to high-quality CE-IVD kits | +0.9% | EU-wide, early in Germany & Netherlands | Short term (鈮� 2 years) |
| Cross-border tele-genetics outreach in underserved Eastern Europe | +0.7% | Eastern Europe & Baltics | Long term (鈮� 4 years) |
| Source: 麻豆视频 | |||
Growing Adoption of NGS-Based Comprehensive Panels by European Healthcare Systems
National health systems now reimburse NGS tumor and rare-disease panels, raising diagnostic yields above 40% versus 25% for sequential single-gene tests. Germany鈥檚 Molecular Tumor Board network covers comprehensive genomic profiling for advanced cancers, while the UK鈥檚 NHS offers free BRCA screening to Jewish women over 30, demonstrating a policy shift toward preventive genomics. Reimbursement clarity pushes laboratories to upgrade capacity, stimulate reagent demand, and invest in cloud-based bioinformatics that integrate directly with electronic clinical records. Device makers respond by launching CE-IVD marked comprehensive assays that bundle tumor mutation burden, microsatellite instability, and gene-fusion profiling in a single test run.
Expansion of Newborn and Population Genomic Screening Programs in EU States
Belgium鈥檚 BabyDetect initiative screens newborns for more than 200 disorders鈥攕upported by EUR 25 million in federal funds鈥攁nd delivers results within two weeks, catching treatable metabolic and immunodeficiency syndromes earlier than biochemical panels. The UK鈥檚 Newborn Genomes Programme is sequencing 200,000 babies to assess actionable variants that can benefit from early interventions such as enzyme-replacement or dietary modifications. These pilots leverage Screen4Care, a EUR 15 million Horizon Europe grant, to standardize genomic data pipelines across seven member states. Data show a 35% rise in early detection of rare diseases, validating program scalability and reinforcing demand for high-throughput sequencers as well as variant-interpretation software.
Falling Sequencing Costs Due to European Infrastructure Investments
Continuous chemistry upgrades and flow-cell redesigns drove whole-genome sequencing below USD 500 per sample in 2024, halving costs since 2022 and broadening clinical utility for pharmacogenomics, pediatric neurology, and complex oncology cases. The Genome of Europe consortium, funded at EUR 1 billion, pools procurement across public laboratories to negotiate reagent discounts and share high-end fleet capacity, reducing per-run overhead. Genomics England processes hospital samples in under 14 days for below USD 400 through robotic sample prep and AI-assisted variant filtration, setting a cost-performance benchmark adopted by German university centers.
Rising Prevalence of Hereditary Cancers Driving Demand for BRCA & Multigene Tests
Updated European oncology guidelines recommend germline testing for all breast- or ovarian-cancer patients under 50, expanding the test-eligible cohort fourfold compared with 2022. Private labs in the UK price multigene cancer panels between GBP 399 and GBP 1,400 (USD 499鈥�1,750), creating an affordable complement to publicly reimbursed single-gene tests. France鈥檚 2025-initiated National Cancer Plan earmarked EUR 50 million to fund family cascade testing, which identifies actionable mutations in 12鈥�15% of relatives versus 5鈥�8% for BRCA-only screening. Resulting demand stimulates counseling and tele-oncology service expansion, while laboratories integrate reflex RNA-based fusion assays to maximize actionable findings from the same biopsy sample.
Restraints Impact Analysis*
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Delays in reimbursement approvals across national health insurers | -1.3% | Southern Europe, Eastern Europe, with particular challenges in Italy, Spain | Medium term (2-4 years) |
| Shortage of certified genetic counselors limiting test uptake | -0.8% | EU-wide, with acute shortages in Eastern Europe, rural areas | Long term (鈮� 4 years) |
| Data sovereignty rules complicating pan-European genomic data sharing | -0.6% | EU-wide, with cross-border implications for Germany, Austria, Netherlands | Medium term (2-4 years) |
| Scarcity of validated polygenic risk scores for non-European ancestries in Europe's migrant populations | -0.4% | Western Europe urban centers, particularly Germany, France, UK | Long term (鈮� 4 years) |
| Source: 麻豆视频 | |||
Delays in Reimbursement Approvals Across National Health Insurers
Italian providers wait 18鈥�24 months for genetic鈥恡est reimbursement decisions, triple the time required in Germany or the Netherlands, undermining equitable access and slowing revenue realization for innovators. Spain鈥檚 autonomous regions each apply divergent coverage criteria, prompting laboratories to navigate 17 distinct approval pathways. The 2024 joint EU Health Technology Assessment Regulation aims to harmonize requirements, but transitional overlap with IVDR doubles dossier workload and prolongs market entry timelines for pharmacogenomics and broad tumor panels. Providers frequently rely on private payment or research grants, dampening volume growth and constraining economies of scale.
Shortage of Certified Genetic Counselors Limiting Test Uptake
Europe requires 4,000 additional certified genetic counselors to meet existing caseloads, yet universities graduate fewer than 200 annually, leaving hospitals to adopt 鈥渕ainstreaming鈥� models that train oncologists and cardiologists to provide limited counseling. The UK employs about 400 counselors for 67 million citizens鈥攚ell below the recommended ratio of 1 per 100,000鈥攆orcing reliance on tele-genetics and group counseling sessions. Eastern Europe faces acute shortages, where cross-border clinics in Vienna and Berlin supply virtual consultations for Baltic and Balkan patients. Prolonged wait times for pre- and post-test counseling discourage physician referrals, particularly for complex prenatal or oncology panels that demand nuanced risk communication.
*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.
Segment Analysis
By Technology: NGS Dominates Clinical Adoption
NGS commanded 40.62% of Europe genetic testing market share in 2025, reflecting its cost-efficient multigene capability and entrenched role in oncology and rare-disease diagnostics. PCR platforms trail yet post the segment鈥檚 fastest 10.91% CAGR as hospitals deploy real-time kits for neonatal sepsis and pharmacogenomics where same-day decisions are critical.
Hospital laboratories standardize workflows around dual-platform strategies that leverage NGS for comprehensive insights and PCR for urgent triage, enabling continuity of operations during instrument maintenance windows. EU IVDR compliance favors vendors with integrated quality-management documentation, prompting smaller kit manufacturers to partner with multinational distributors. As throughput increases, reagent-rental contracts lower upfront costs, supporting wider adoption among mid-size pathology networks.
By Application: Cancer Leads, Wellness Accelerates
Oncology accounted for 47.10% of Europe genetic testing market size in 2025 as molecular tumor boards embedded profiling into every advanced-cancer case, unlocking targeted-therapy reimbursements. Conversely, ancestry & wellness use cases climb fastest at 11.05% CAGR, propelled by social-media-driven consumer demand for lifestyle insights.
Diagnostic labs expand somatic-plus-germline combo tests that inform both therapy and familial risk, boosting panel average selling prices. Direct-to-consumer firms localize websites in 23 EU languages and partner with pharmacies for sample logistics, mitigating regulatory scrutiny over cross-border data transfers. Wellness kits increasingly upsell pharmacogenomic add-ons that convert casual users into repeat purchasers through app-based medication dashboards.
By End User: Hospitals Anchor, Labs Accelerate
Hospitals & clinics captured 51.44% of Europe genetic testing market share in 2025 thanks to embedded precision-oncology and neonatal screening services. Diagnostic laboratories, however, will grow fastest at 11.55% CAGR as payers push outpatient models and specialists outsource complex bioinformatics.
University hospitals build hub-and-spoke models in which regional clinics send samples centrally, ensuring uniform variant interpretation. Commercial labs differentiate through 48-hour panel turnaround and AI-powered reports that flag clinical-trial eligibility, enticing oncologists seeking real-time therapeutic pathways. Remote counseling platforms integrate lab portals with certified genetic counselors in under-served geographies, expanding patient reach while reducing referral leakage.
Geography Analysis
Germany contributed 24.05% of Europe genetic testing market size in 2025 by virtue of universal health-insurance reimbursement for tumor and pharmacogenomic panels and a dense network of academic genomics centers. The United Kingdom remains pivotal, leveraging the NHS Genomic Medicine Service鈥檚 single-payer purchasing power to standardize test menus and volume-based discounts. France follows through a EUR 670 million national strategy that builds 30 sequencing hubs linked to secure cloud analytics, accelerating rare-disease case resolutions from 22 to 12 months.
Italy and Spain show improving uptake yet continue to face fragmented reimbursement, prompting patients to seek private tests or cross-border referrals. Eastern European markets鈥擝ulgaria, Romania, Poland, and the Baltics鈥攑ost the fastest 11.72% CAGR as EU structural funds finance infrastructure and tele-genetics bridges supply shortages. Vienna鈥檚 Medical University, for example, supports variant interpretation for Balkan oncology centers via encrypted cloud pipelines, evidencing collaborative momentum. Harmonized GDPR protocols ease cross-border data exchange, enhancing multinational research consortia that accelerate variant re-classification and clinical guideline updates.
Regulatory Landscape
Genetic testing assays and instruments marketed in Europe are treated as in vitro diagnostic medical devices under Regulation (EU) 2017/746 (IVDR). Under Annex VIII (including Rule 3i), many human genetic testing devices fall into higher-risk classifications, which raises the level of conformity assessment, expands performance evidence expectations, and tightens post-market oversight versus the legacy IVD Directive.
Market access still depends heavily on implementation capacity and transition timing. Regulation (EU) 2024/1860 (in force from 9 July 2024) extended certain IVDR transitional provisions to mitigate certification bottlenecks and reduce shortage risk. In parallel, European Commission updates through June 2026 continued to track Notified Body designation pipeline activity, including new applications for designation. The IVDR also includes a mandated European Commission evaluation by May 2027, which keeps compliance requirements and guidance actively evolving through the study period.
Value Chain Analysis
The Europe genetic testing value chain begins with upstream consumables and platform inputs (sample collection devices, extraction chemistries, enzymes, probes/primers, flow cells, and controls), followed by instrument manufacturing for NGS, PCR, microarray, and supporting automation. Midstream, clinical and commercial laboratories run pre-analytical accessioning and sample preparation, perform sequencing or amplification, and apply quality control through IVDR-aligned quality management systems. They then convert raw outputs into clinical-grade results via bioinformatics pipelines and variant interpretation.
Downstream value is shaped by software providers and clinical networks that embed reports into electronic health records and care pathways (oncology, rare disease, newborn screening, and pharmacogenomics), along with counseling and referral workflows. Specialized examples reflect how the chain is assembled in practice: Medicover Genetics uses Bionano Saphyr optical mapping as an adjunct to standard NGS for structural-variant resolution, and providers such as SOPHiA GENETICS supply analytics layers used by labs to scale interpretation. Regulatory-linked supply assurance is increasingly built into operating models. Under Regulation (EU) 2024/1860, manufacturers must provide advance notice (at least six months) to authorities and operators for certain anticipated supply interruptions or discontinuations, which affects procurement planning and dual-sourcing decisions for critical reagents and kits.
Competitive Landscape
The arena remains moderately fragmented: Illumina, Roche, and Quest Diagnostics anchor high-throughput sequencing and distribution, while Centogene, Eurofins Scientific, and Oxford Nanopore supply region-specific assays and long-read platforms. Consolidation is gaining pace; Eurofins鈥� EUR 120 million acquisition of SYNLAB Spain added 15 labs and doubled Iberian capacity, whereas Labcorp partnered with SYNLAB to broaden reach in Central and Eastern Europe.
Technology differentiation centers on AI-assisted interpretation and multi-omics capability. Oxford Nanopore invested EUR 50 million in German manufacturing to localize supply and comply with IVDR batch-release documentation. Emerging entrants leverage tele-counseling and direct-to-consumer storefronts but must overcome rising compliance costs that favor well-capitalized players. Patent filings for bioinformatics algorithms at the European Patent Office surged 23% in 2024, signaling intensifying innovation races around variant-classification and polygenic-risk scoring.
Europe Genetic Testing Industry Leaders
Abbott Laboratories
Illumina Inc.
23andMe Inc.
Qiagen
F. Hoffmann-La Roche Ltd
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
IVDR-driven re-certification and portfolio refresh create opportunities for suppliers that can provide compliant, clinically validated assays for underserved indications and geographies. A case in point is Devyser Diagnostics AB, which launched Devyser Thalassemia v2 in April 2026 as an IVDR-compliant NGS assay for hemoglobinopathies. This supports broader use of genetic testing beyond oncology, including reproductive and inherited disease workflows where many laboratories have historically relied on LDTs. Regional procurement can also be a practical scaling path in Southern and Eastern Europe, exemplified by Devyser winning a five-year tender in Regione Basilicata (Italy) in June 2026 covering CFTR, thalassemia, and male infertility diagnostics.
Oncology testing continues to expand from tissue-based profiling into blood-based applications and companion diagnostics tied to therapy decisions, supported by partnerships and regulatory approvals. In May 2026, SOPHiA GENETICS partnered with Synnovis to deploy MSK-ACCESS liquid biopsy testing across the UK for lung and breast cancer, highlighting demand for end-to-end workflows that pair wet-lab testing with AI-enabled interpretation. On the product and compliance front, MRC Holland received CE-IVDR certification in June 2026 for a cancer-predisposition assay (PMS2). In April 2026, Eurobio Scientific signed a definitive agreement to acquire CareDx鈥檚 Lab Products division (EUR 145 million), reinforcing ongoing consolidation and portfolio expansion across specialized genetic and molecular testing categories, including transplant-related diagnostics, in Europe.
Recent Industry Developments
- June 2026: Roche reported EU IVDR approval for label expansions of its VENTANA MMR RxDx Panel companion diagnostic across multiple solid tumor types. The update broadens the eligible testing use cases within regulated oncology pathways and reinforces the trend toward IVDR-compliant companion diagnostics that align therapy selection with standardized molecular results.
- June 2025: Illumina finalized its acquisition of SomaLogic for USD 350 million to add high-plex proteomics capabilities alongside genomics offerings used by European laboratories. The combination supports multi-omics test development and can strengthen lab relationships by bundling discovery-to-clinical workflows under a single vendor.
- April 2024: Eurofins Scientific acquired SYNLAB Spain for EUR 120 million, adding 15 laboratories and expanding Iberian diagnostic capacity. The deal strengthened Eurofins鈥� presence with hospitals and payers in Spain, supporting scale advantages for centralized genetic testing operations and associated IVDR compliance investments.
Research Methodology Framework and Report Scope
Market Definition and Coverage
For this study, the Europe genetic testing market covers revenue generated from genetic tests and related testing services used for screening, diagnosis, and risk assessment, where the output is a genetic result used by a clinician, lab, or patient pathway.
Scope exclusions: We exclude genetic research-only sequencing that is not reported as a clinical or screening test revenue stream.
Segmentation Overview
- By Technology (Value)
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Microarray
- Fluorescence In Situ Hybridization (FISH)
- Sanger Sequencing
- Other Technologies
- By Application (Value)
- Cancer Diagnosis & Prognosis
- Cardiovascular Disease Diagnosis
- Neurological Disorder Diagnosis
- Ancestry & Wellness
- Other Applications
- By End User (Value)
- Hospitals & Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Direct-to-Consumer Companies
- Other End Users
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
Data Sources, Market Sizing, and Validation
Desk Research
Desk research started with public healthcare and demographic signals that explain demand for testing and the readiness of systems to pay for it. Sources used include, for example, Eurostat for population and health statistics, the European Commission and ECDC for policy and screening context, OECD health data for spend and access indicators, and WHO Europe for disease burden reference points.
We also reviewed scientific and regulatory signals that affect real testing volumes and pricing, such as peer reviewed journals on NGS and molecular diagnostics uptake, national health service and ministry publications in major European countries, and lab and manufacturer public materials like annual reports and investor presentations. For cross-checks, we used paid subscriptions for company financials and patent databases to confirm activity patterns where public detail was thin. The sources listed here are illustrative, and other documents were also used to collect, verify, and clarify the data used in the model.
Primary Interviews and Surveys
Primary work focused on validating how testing volumes move through labs and hospitals, and how average selling prices vary by test purpose and technology. We spoke with clinical laboratory leaders, hospital procurement and pathology teams, test developers, and distributors across major European countries, and the inputs were then used to tighten gaps in reimbursement coverage, adoption timing, and the mix between private pay and covered testing.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 32% | CXOs: 12% | |
| Mid tier: 50% | Functional/Unit leaders: 30% | |
| Smaller Players: 18% | Managers: 58% |
Market-Sizing & Forecasting
Sizing was built using a mix of top-down and bottom-up checks so the final totals stayed tied to actual testing activity. On the top-down side, we reconstructed demand pools by combining healthcare utilization and disease screening intensity with the share of patients routed to genetic tests, and then translated those volumes into revenue using typical price bands by test type and technology.
Key inputs tracked (as illustrative examples) included adoption of molecular and NGS based workflows, test mix shifts between screening and diagnostic use, reimbursement direction under EU IVDR related compliance pressures, laboratory throughput capacity signals, and country level funding and program rollout pace for newborn and hereditary risk testing. Forecasts were produced using scenario analysis, where uptake and pricing were stressed under faster and slower reimbursement expansion, and then aligned to the consensus direction from experts.
Bottom-up approximations were used as a reasonableness check, mainly through selective roll-ups of reported revenues and sampled volume times ASP calculations across representative labs and suppliers. Where data was missing for smaller countries, ratios were imputed using comparable country healthcare intensity and testing adoption indicators, and then reviewed again during validation.
Data Validation & Update Cycle
Validation was done through multiple checks so outliers did not pass through unnoticed. Model outputs were compared against independent signals such as reported lab throughput, public screening program activity, and disclosed revenue trajectories of active participants, and any large variance was reviewed and adjusted with documented reasoning.
Before sign-off, the work is reviewed in steps, starting with assumption checks, followed by consistency checks across countries, and then a final analyst review that re-reads the key inputs and calculations. Reports are refreshed annually, with interim updates when material events occur, and a fresh pre-delivery review is completed so clients receive the most current view.
麻豆视频's Europe Genetic Testing Market Market Size Compared Against Other Published Estimates
Published market values for Europe genetic testing do not always match because the market can be counted through very different lenses, and each lens changes what gets included in the revenue total. Differences often come from whether consumer DNA kits are counted the same way as clinical tests, how pricing is averaged across countries, and how quickly assumptions are refreshed when reimbursement or test mix shifts.
Direct-to-consumer ancestry and ethnicity testing sits outside 麻豆视频's scope, which is why some figures that lean heavily on consumer applications can look lower or higher depending on how they net out test kit pricing and repeat purchase behavior. Beyond scope, gaps also come from the year used as the base case, the way exchange rates are applied for multi-country totals, and whether pricing is held flat or updated as NGS panels and multi-gene tests become more common.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| 麻豆视频 | USD 6.82 B (2025) | |
| Trade Journal A | USD 3.31 B (2024) | The figure is anchored in a 2024 databook view with application shares that appear to be heavily weighted to consumer ancestry use, which can understate clinical diagnostic and screening revenue if lab service pricing is not fully captured. |
| Regional Consultancy B | USD 4.79 B (2024) | The estimate is based on a 2024 starting point and can differ if it uses a narrower set of reimbursed clinical pathways, or if country level pricing and test mix shifts are averaged without adjusting for higher value molecular panels. |
The spread across the three numbers mainly reflects scope and what is treated as clinical testing revenue versus consumer use, followed by base year timing and pricing updates. By tying the model to test volumes, technology adoption, and country specific reimbursement direction, the final market size stays traceable to inputs that can be rechecked and repeated over time.
Key Questions Answered in the Report
How large is the Europe genetic testing market in 2026?
The market is valued at USD 7.52 billion in 2026 with a forecast 10.31% CAGR to 2031.
Which technology leads clinical adoption across Europe?
Next-generation sequencing holds 40.62% share, firmly anchoring complex oncology and rare-disease diagnostics.
Why is Germany the largest national contributor?
Germany's universal reimbursement, academic genomics hubs, and Molecular Tumor?Board network secure a 24.05% share of regional revenues.
What hampers faster expansion in Southern Europe?
Lengthy reimbursement approvals18-24 months in Italy and similar delays in Spain slow public adoption of new tests.
How are newborn screening programs evolving?
Initiatives like Belgium's BabyDetect and the UK's Newborn Genomes Programme add whole-genome sequencing to traditional panels, improving early rare-disease detection by 35%.
Which segment shows the fastest future growth?
Direct-to-consumer ancestry & wellness testing is projected to rise at a 11.05% CAGR as consumers embrace personalized health insights.
Page last updated on:
